Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Adenocarcinoma 1

Interventions

Cyclophosphamide 2068Radiotherapy 1990Cisplatin 1857Carboplatin 1560Gemcitabine 1455Paclitaxel 1322Bevacizumab 1321pembrolizumab 1240Docetaxel 1227Oxaliplatin 1184Capecitabine 1179Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 973Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 641Lenalidomide 619Biopsy 595Specimen Handling 570

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × LY3022855 × Clear all
NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
11 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
5 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡